Scholar Rock’s stock price increased by 362% after the company announced data from the Phase III SAPPHIRE trial of ...
Johnson & Johnson has discontinued its SunRISe-2 study for TAR-200 in bladder cancer patients not undergoing radical ...
The trial will assess Intellia Therapeutics’ investigational in-vivo gene editing therapy for hereditary angioedema. Credit: Intellia Therapeutics. US-based biotechnology company Intellia Therapeutics ...
AstraZeneca’s Airsupra is currently approved in the US for as-needed treatment or prevention of bronchoconstriction. Credit: Jennie Book/Shutterstock. UK-based pharmaceutical company AstraZeneca has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback